Combination Cancer Therapy is Focus of $1M Merck Research Grant Received by NCCN
NCCN has been awarded a $1M research grant from Merck & Co, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza®). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, panc...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Cutaneous T cell lymphoma | Grants | Lung Cancer | Lymphoma | Merck | Non-Small Cell Lung Cancer | Radiation Therapy | Study | T-cell Lymphoma